C
Catherine Boisson-Vidal
Researcher at Paris Descartes University
Publications - 6
Citations - 75
Catherine Boisson-Vidal is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Endothelial stem cell & Fucoidan. The author has an hindex of 4, co-authored 6 publications receiving 60 citations.
Papers
More filters
Journal ArticleDOI
Type 2 diabetes alters mesenchymal stem cell secretome composition and angiogenic properties.
Jonathan Ribot,Guavri Caliaperoumal,Joseph Paquet,Catherine Boisson-Vidal,Hervé Petite,Fani Anagnostou +5 more
TL;DR: It is demonstrated that BMMSCs from T2DM rats have a unique secretome with distinct angiogenic properties and provide new insights into the role of BMMSC in aberrant angiogenesis in the diabetic milieu.
Journal ArticleDOI
Fucoidan Stimulates Monocyte Migration via ERK/p38 Signaling Pathways and MMP9 Secretion.
TL;DR: Fucoidan displays striking biological effects, notably promoting monocyte adhesion and migration, which involve the ERK and p38 pathways, and increased MMP9 activity.
Journal ArticleDOI
Downregulation of Microparticle Release and Pro-Inflammatory Properties of Activated Human Polymorphonuclear Neutrophils by LMW Fucoidan.
João Alfredo Moraes,João Alfredo Moraes,Ana Clara Frony,Pedro Barcellos-de-Souza,Marcel Menezes da Cunha,Thayanne B. B. Calcia,Claudia F. Benjamim,Catherine Boisson-Vidal,Christina Barja-Fidalgo +8 more
TL;DR: The low- molecular-weight fucoidan (LMW-Fuc), a polysaccharide extracted from brown algae, attenuated the exacerbated activation induced by fMLP on LPS-primed PMNs, in vitro, impairing chemotaxis, NET formation, and the pro-survival and pro-oxidative effects.
Journal ArticleDOI
Osteoprotegerin Induces CD34+ Differentiation in Endothelial Progenitor Cells.
Catherine Boisson-Vidal,Zahia Benslimane-Ahmim,Anna Lokajczyk,Dominique Heymann,David M. Smadja +4 more
TL;DR: The findings provide novel insights into OPG in regulation of CD34+ progenitor cells and give new opportunities for ex vivo expansion of human ECFCs using OPG as a cell culture component for future ECFC product manufacture according to GMP.
Journal ArticleDOI
La résistance aux traitements antiangiogéniques - Une actualité clinique et scientifique
Yuchen Gu,He Lu,Catherine Boisson-Vidal,Hong Li,Guilhem Bousquet,Anne Janin,Mélanie Di Benedetto +6 more
TL;DR: The approach is still valid since this therapeutic tool has lengthened survival of patients with colon, breast, kidney, lungs and liver cancers and the identification of biomarkers in response to this family of drugs is an important area of investigation.